Regulatory Approvals Advance D-PLEX₁₀₀ in US and EU
1 report, 1 independent
Updated Oct 9
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency validated a Marketing Authorization Application for D-PLEX₁₀₀, granting single authorization across EU states. Separately, the product received Priority Review from the FDA. This regulatory progress follows PolyPid regaining full European commercialization rights to the product from ADVANZ PHARMA.
From investegate.co.uk
Why it matters
The regulatory validation by the European Medicines Agency and the FDA Priority Review advance the commercial viability of D-PLEX₁₀₀ in major global markets. These approvals confirm the product's potential market access and sales opportunities.
From investegate.co.uk
Who's involved
- FDARegulatory agency reviewing the product in the United States.
- European Medicines AgencyRegulatory authority that validated the product application across the European Union.
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- Unregulated products are bypassing official government approval processes.
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- FDA and Pfizer are seeking regulatory approval for their products.
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
- Arise is seeking FDA approval for a drug as of October 7, 2026.